Rajvilas A Narkhede1, Gunjan S Desai2, Pande P Prasad3, Prasad K Wagle4. 1. Junior Consultant, Department of Gastrointestinal Surgery, Lilavati Hospital and Research Center, Mumbai, India, rajvilas.narkhede@gmail.com. 2. Clinical Associate, Department of Gastrointestinal Surgery, Lilavati Hospital and Research Center, Mumbai, India. 3. Department of Gastrointestinal Surgery, DNB Gastrointestinal Surgery Third Year Resident, Lilavati Hospital and Research Center, Mumbai, India. 4. Consultant, Department of Gastrointestinal Surgery, Lilavati Hospital and Research Center, Mumbai, India.
Abstract
BACKGROUND: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in patients with CP on long-term follow-up. SUMMARY: This review consolidates the existing literature on assessment of PDAC in background of CP, its evaluation through the available investigations, surgical management, and prognostication. Recent change in symptomatology of an otherwise stable CP should raise a suspicion of malignancy. Endoscopic ultrasound (EUS) is more specific and sensitive in establishing the diagnosis of PDAC compared to cross-sectional imaging (computed tomography/magnetic resonance imaging). Intraoperative assessment with careful palpation coupled with careful clinical judgment helps in differentiating between an inflammatory mass and pancreatic cancer. Confirmation can be obtained with either preoperative EUS-guided fine needle cytology/core biopsy or intraoperative core biopsy under ultrasound guidance. However, despite complete evaluation with above options, 1-6% patients often show malignancy on final histopathological examination. Key Messages: Diagnosis of PDAC in CP needs a high index of suspicion. Cross-sectional imaging has poor negative predictive value. CA 19-9 with MUC5AC combination may become an ideal investigation. EUS with core biopsy/frozen section has a good sensitivity and specificity and low false negative results. Complete radical resection should be the aim to get long-term survival.
BACKGROUND: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in patients with CP on long-term follow-up. SUMMARY: This review consolidates the existing literature on assessment of PDAC in background of CP, its evaluation through the available investigations, surgical management, and prognostication. Recent change in symptomatology of an otherwise stable CP should raise a suspicion of malignancy. Endoscopic ultrasound (EUS) is more specific and sensitive in establishing the diagnosis of PDAC compared to cross-sectional imaging (computed tomography/magnetic resonance imaging). Intraoperative assessment with careful palpation coupled with careful clinical judgment helps in differentiating between an inflammatory mass and pancreatic cancer. Confirmation can be obtained with either preoperative EUS-guided fine needle cytology/core biopsy or intraoperative core biopsy under ultrasound guidance. However, despite complete evaluation with above options, 1-6% patients often show malignancy on final histopathological examination. Key Messages: Diagnosis of PDAC in CP needs a high index of suspicion. Cross-sectional imaging has poor negative predictive value. CA 19-9 with MUC5AC combination may become an ideal investigation. EUS with core biopsy/frozen section has a good sensitivity and specificity and low false negative results. Complete radical resection should be the aim to get long-term survival.
Authors: Sebastian Dwertmann Rico; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Daniel Perez; Jakob R Izbicki; Michael Neipp; Hamid Mofid; Thies Daniels; Christoph Isbert; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Eike Burandt; Andreas Marx; Till Krech Journal: Int J Immunopathol Pharmacol Date: 2022 Jan-Dec Impact factor: 3.298
Authors: Sebastian Dwertmann Rico; Moritz Mahnken; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Christina Möller-Koop; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Frank Jacobsen; Patrick Lebok; Till S Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Sarah Minner; Eike Burandt; Till Krech; Andreas H Marx Journal: Technol Cancer Res Treat Date: 2021 Jan-Dec
Authors: Puvanesswaray Ramakrishnan; Wei Mee Loh; Subash C B Gopinath; Srinivasa Reddy Bonam; Ismail M Fareez; Rhanye Mac Guad; Maw Shin Sim; Yuan Seng Wu Journal: Acta Pharm Sin B Date: 2019-11-14 Impact factor: 11.413